Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 May 19;40(7):3087–3103. doi: 10.1007/s12325-023-02497-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Fig. 1 — Selection of imatinib studies for the MAIC analysis. CDSR Cochrane Database of Systematic Reviews, CENTRAL Cochrane Central Register of Controlled Trials, DARE Database of Abstracts of Reviews of Effectiveness, MAIC matching adjusted indirect comparison, SLR systematic literature review. *Study only reported median age of patients. **The SLR identified 18 unique studies investigating imatinib-based regimens for patients with newly diagnosed Philadelphia chromosome-positive acute lymphocytic leukemia. Studies that did not follow a treatment of interest (i.e., induction without imatinib; not from a German multicenter study group for adult acute lymphoblastic leukemia protocol for hyper-CVAD; imatinib not given continuously) or that reported too few baseline characteristics to allow a meaningful population-adjustment were excluded from the MAIC analysis